AZN vs PACB · P/E 28, $288.38B cap vs rev $76.2M
AstraZeneca PLC (AZN) versus Pacific Biosciences of California (PACB) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
AZN does not have a complete income-statement cache yet.
Latest reported PACB revenue for 2026-06-30 was $76.2M. Net income was -$53.0M. PACB currently screens at market cap $387.1M.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. PACB currently screens at market cap $387.1M.
Not investment advice. Open the AZN and PACB stock pages for the full models.
Not investment advice.